$COGT has been mentioned 9 times over the past 12 months by 2 distinct FinTwit voices, with the first mention appearing on October 1, 2025. @jacobplieth (@jacobplieth) is the most active voice discussing the stock, contributing 17 mentions, while @adamfeuerstein (@adamfeuerstein) has 2 mentions. The biotech category represents the primary discussion focus for $COGT among these voices.

Recent discussion of $COGT centers on clinical and competitive developments. On March 27, 2026, @jacobplieth posted that "$COGT next to discontinue CGT6297 and switch to wild-type sparing inhibitors," and the same day noted the stock opening down 17%. Earlier that week, on March 20, @jacobplieth contextualized $COGT within a broader trend, observing that "$NVS follows $LLY into mutation-selective PI3Kα inhibition. What does this mean for $RLAY $OKUR & $COGT?"